A call for action in bleeding prevention.
作者信息
Gragnano Felice, Manavifar Negar, Valgimigli Marco
机构信息
Department of Cardiology, Bern University Hospital, University of Bern, Bern 3010, Switzerland.
出版信息
Aging (Albany NY). 2019 Jan 11;11(2):287-288. doi: 10.18632/aging.101745.
Abstract
摘要
相似文献
1
A call for action in bleeding prevention.预防出血的行动呼吁。
Aging (Albany NY). 2019 Jan 11;11(2):287-288. doi: 10.18632/aging.101745.
2
What is the optimal antithrombotic strategy in primary percutaneous coronary intervention?在经皮冠状动脉介入治疗中，最佳的抗血栓治疗策略是什么？
Curr Opin Cardiol. 2012 Jul;27(4):361-7. doi: 10.1097/HCO.0b013e3283540828.
3
[Bleeding risk related to combined aspirin and other antithrombotic drug use in patients with acute coronary syndrome: prevention and therapy strategies].[急性冠脉综合征患者联合使用阿司匹林与其他抗血栓药物的出血风险：预防与治疗策略]
Zhonghua Xin Xue Guan Bing Za Zhi. 2010 Dec;38(12):1057-9.
4
A risk score to predict bleeding in patients with acute coronary syndromes.用于预测急性冠脉综合征患者出血风险的评分。
J Am Coll Cardiol. 2010 Jun 8;55(23):2556-66. doi: 10.1016/j.jacc.2009.09.076.
5
The score is in but is the decision final?分数已出，但决定是最终的吗？
J Am Coll Cardiol. 2010 Jun 8;55(23):2567-9. doi: 10.1016/j.jacc.2010.02.037.
6
Management of acute coronary syndrome: achievements and goals still to pursue. Novel developments in diagnosis and treatment.急性冠状动脉综合征的管理：成就与仍待追求的目标。诊断与治疗的新进展。
J Intern Med. 2012 Jun;271(6):521-36. doi: 10.1111/j.1365-2796.2012.02533.x. Epub 2012 Mar 26.
7
[Reduction of haemorrhagic risk in acute coronary syndromes].[降低急性冠状动脉综合征的出血风险]
Med Clin (Barc). 2011 Nov 26;137(14):650-5. doi: 10.1016/j.medcli.2010.05.015. Epub 2010 Aug 10.
8
Combined Use of Bivalirudin and Radial Access in Acute Coronary Syndromes Is Not Superior to the Use of Either One Separately: Meta-Analysis of Randomized Controlled Trials.比伐卢定联合桡动脉入路与单独使用比伐卢定或桡动脉入路治疗急性冠状动脉综合征的疗效比较：随机对照试验的荟萃分析。
JACC Cardiovasc Interv. 2016 Aug 8;9(15):1523-31. doi: 10.1016/j.jcin.2016.05.023.
9
Incidence, outcomes, and management of bleeding in non-ST-elevation acute coronary syndromes.非 ST 段抬高型急性冠状动脉综合征患者的出血发生率、结局和管理。
Cleve Clin J Med. 2010 Jun;77(6):369-79. doi: 10.3949/ccjm.77a.09142.
10
Major bleeding: management and risk reduction in acute coronary syndromes.严重出血：急性冠状动脉综合征的管理与风险降低
Expert Opin Pharmacother. 2008 Aug;9(11):1869-83. doi: 10.1517/14656566.9.11.1869.
引用本文的文献
1
No free lunch-the price of double versus triple antithrombotic therapy in patients with atrial fibrillation after ACS or PCI.没有免费的午餐——急性冠状动脉综合征或经皮冠状动脉介入治疗后房颤患者双联与三联抗栓治疗的代价。
Ann Transl Med. 2020 Apr;8(7):516. doi: 10.21037/atm.2020.01.26.
本文引用的文献
1
Radial vs femoral access for the prevention of acute kidney injury (AKI) after coronary angiography or intervention: A systematic review and meta-analysis.经桡动脉与股动脉入路对冠状动脉造影或介入术后急性肾损伤（AKI）预防的系统评价与荟萃分析。
Catheter Cardiovasc Interv. 2018 Dec 1;92(7):E518-E526. doi: 10.1002/ccd.27903. Epub 2018 Sep 23.
2
Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial.经皮冠状动脉介入治疗的急性冠状动脉综合征患者中桡动脉入路与股动脉入路和比伐卢定与普通肝素的比较（MATRIX）：一项多中心、随机对照试验的最终 1 年结果。
Lancet. 2018 Sep 8;392(10150):835-848. doi: 10.1016/S0140-6736(18)31714-8. Epub 2018 Aug 25.
3
Bivalirudin or Heparin in Patients Undergoing Invasive Management of Acute Coronary Syndromes.比伐卢定或肝素在接受急性冠状动脉综合征有创治疗的患者中的应用。
J Am Coll Cardiol. 2018 Mar 20;71(11):1231-1242. doi: 10.1016/j.jacc.2018.01.033.
4
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).2017年欧洲心脏病学会（ESC）与欧洲心胸外科学会（EACTS）合作制定的冠状动脉疾病双联抗血小板治疗重点更新：欧洲心脏病学会（ESC）和欧洲心胸外科学会（EACTS）冠状动脉疾病双联抗血小板治疗特别工作组。
Eur Heart J. 2018 Jan 14;39(3):213-260. doi: 10.1093/eurheartj/ehx419.
5
Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial.急性冠状动脉综合征后心肌梗死与出血类型对死亡率的权衡：来自急性冠状动脉综合征临床事件减少凝血酶受体拮抗剂（TRACER）随机试验的经验教训。
Eur Heart J. 2017 Mar 14;38(11):804-810. doi: 10.1093/eurheartj/ehw525.
6
Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes.比伐卢定或普通肝素治疗急性冠脉综合征。
N Engl J Med. 2015 Sep 10;373(11):997-1009. doi: 10.1056/NEJMoa1507854. Epub 2015 Sep 1.
7
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC).2015年欧洲心脏病学会（ESC）非持续性ST段抬高型急性冠脉综合征患者管理指南：欧洲心脏病学会（ESC）非持续性ST段抬高型急性冠脉综合征患者管理工作组
Eur Heart J. 2016 Jan 14;37(3):267-315. doi: 10.1093/eurheartj/ehv320. Epub 2015 Aug 29.
8
Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial.经皮冠状动脉介入治疗的急性冠状动脉综合征患者中桡动脉与股动脉入路的随机多中心试验。
Lancet. 2015 Jun 20;385(9986):2465-76. doi: 10.1016/S0140-6736(15)60292-6. Epub 2015 Mar 16.
Zotero 插件